1 completed, 1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Brian Jonas: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure Azacitidine, Decitabine, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 2 | Recruiting | Brian Jonas | 20 | 2022-02-09 | 2024-05-29 |
| Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia Azacitidine, Uproleselan, Venetoclax - Acute Myeloid Leukemia | Phase 1 | Terminated | Brian Jonas | 16 | 2021-07-02 | 2026-02-23 |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Azacitidine, Ibrutinib - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 | Completed | Brian Jonas | 21 | 2016-05-17 | 2022-10-06 |
Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (1)
Azacitidine (3) · venetoclax (2) · Decitabine (1) · Injections (1) · ibrutinib (1) · uproleselan (1)
United States (3)
Brian A Jonas (2)
P30CA093373 (2)